News that Nabi Biopharmaceuticals intends to continue development of its Gram-positive programs - which includes the lead drugs StaphVAX and Altastaph - restored investor hopes Wednesday, as the company’s stock climbed 15.8 percent. (BioWorld Today) Read More
No Abstract Staff WriterThough it represents the most prolific biotech industry in the Asia-Pacific region, Australia is a land of untapped early stage drug discoveries.A haven for research and innovation led by more than 400 biotech firms, many of them spun out of local universities and research institutes, the country down under has faced challenges in attracting venture capital funding. Read More
